Home > Haematology > ASH 2019 > CAR T and Beyond > Anti-BCMA/anti-CD38 in refractory multiple myeloma

Anti-BCMA/anti-CD38 in refractory multiple myeloma

Presented By
Prof. Yu Hu, Huazhong University of Science and Technology, China
Conference
ASH 2019
In the first clinical trial of a novel, bispecific anti-BCMA and CD38 dual-targeted chimeric antigen receptor (CAR) T-cell therapy in refractory multiple myeloma, results demonstrated promising responses and a manageable safety profile [1]. The dose-escalation phase 1 trial, presented by Prof. Yu Hu (Huazhong University of Science and Technology, China), included 22 patients with multiple myeloma that had returned or not responded to at least 3 prior therapies. Of the 22 patients, 9 (41%) had extramedullary tumours. Myeloma cells in the bone marrow were observed at a median of 9.7% (0.50% to 56.1%) by flow cytometry; and 73% of patients had cytogenetic abnormalities such as amplified 1q21 (54.6%) or deletion of chromosome 13q (40.9%). All patients were treated with fludarabine at 25 mg/m2 and cyclophosphamide 250 mg/m2 before infusion with the engineered CAR T cells. Patients were infused with CAR T cells at 0.5 × 106/kg to 4.0 × 106/kg with at leas...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on